First-time generic approvals (October 2006)
Trimipramine capsules, 25, 50, and 100 mg (equiv to Surmontil capsules)
Trimipramine capsules, 25, 50, and 100 mg (equiv to Surmontil capsules)
AMIDE PHARMACEUTICAL
Venlafaxine tablets, 25, 37.5, 50, 75, and 100 mg (equiv to Effexor tablets)
Ciprofloxacin injection, 10 mg/mL, packaged in 200 mg/20 mL and 400 mg/40 mL single-use vials (equiv to Cipro IV injection)
ABRAXIS, SICOR, HOSPIRA, BEDFORD
Ciprofloxacin injection, 10 mg/mL, packaged in a 1,200 mg/120 mL single-use vial (pharmacy bulk package) (equiv to Cipro IV injection)
BEDFORD
Lamotrigine tablets 25, 100, 150, and 200 mg (equiv to Lamictal tablets)
TEVA
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
